Currently, common therapies for melanoma include targeted inhibitors of BRAFV600E and MEK kinases in the mitogen activated protein kinase (MAPK) pathway, interleukin-2 (IL-2), oncolytic viruses, interferon, and emerging immune checkpoint inhibitors (ICI) alone or in combination. Here, MAP2K7 is linked to melanoma.